-
Ann Rheum Dis: Is rheumatoid arthritis targeted therapy really effective? Patient Queue Longitudinal Analysis (RA BIODAM)
Time of Update: 2020-05-29
The study aims to explore whether the goal of targeting ( T2T ) strategies in daily clinical practice can lead to more patients with rheumatoid arthritis ( RA ) to achieve remission goals a dis
-
Takeda's Vidoju mono-resistance is approved in China for the treatment of moderate to severe active ulcerative colitis and Crohn's disease
Time of Update: 2020-05-29
Takeda Pharmaceuticals announced that its Entyvio (Vidoju mono-resistance) is approved by the China Drug Administration (NMPA) for the treatment of adult patients with moderate to severe active ulc
-
Ann Rheum Dis: Breast cancer risk and the effects of hormone factors before and after rheumatoid arthritis
Time of Update: 2020-05-29
The study aims to explore the risk of breast cancer in women with rheumatoid arthritis (RA) and the risk of RA in women with a history of breast cancer, taking into account anti-hormonal therapy fo
-
Ann Rheum Dis: The Financial Burden of Rheumatoid Arthritis
Time of Update: 2020-05-29
Over the past few decades, the treatment of rheumatoid arthritis (RA) has made rapid progress In particular, the emergence of biological and targeted synthetic diseases to improve the presence of a
-
Semin Arthritis Rheu: Incidence of COVID-19 in rheumatologists treated with tDMARDs
Time of Update: 2020-05-29
The study was designed to investigate the incidence of neo-coronavirus COVID-19 in adult and child rheumatic patients treated with targeted biologics and synthetic diseases to improve anti-rheumati
-
Open Rheumatol J: Study finds weight loss should be included in treatment for obese OA patients
Time of Update: 2020-05-29
Compared to intermittent ceresibu therapy, this study aims to characterize the efficacy of body mass index (BMI) in the daily continuous treatment of ceresib pre-exploratory analysis of a 24-wee
-
Sci Rep: Systemic lupus gastrointestinal strain
Time of Update: 2020-05-29
Systemic lupus (SLE) gastrointestinal (GI) complications are characterized by multiple segments and multiple organ fatigue The aim of the study was to create a system based on computer tomography (
-
European Medicines Agency: Advanced Therapeutic Classification granted to MB-107 slow virus gene therapy for the treatment of X chain of severe comprehensive immunodeficiency disease
Time of Update: 2020-05-29
Mustang is a clinical biopharmaceutical company dedicated to the treatment of hematologic tumors, solid tumors and rare genetic diseases using cell and gene therapy Recently, the European Medicines
-
Nat Commun: New breakthrough, immune system swallows cancer cells with increased appetite
Time of Update: 2020-05-29
Introduction: Glioblastoma is the most malignant glioma in astrocyte tumors, the growth rate is extremely fast, 70% to 80% of patients in 3 to 6 months, the course of more than 1 year only 10%, aft
-
J Rheumatol: Changes in attachment points due to age, body mass index and physical activity: ultrasound study of healthy populations
Time of Update: 2020-05-29
The purpose of this study was to investigate the prevalence of ultrasound (US) lesions and their influencing factors at health attachment sites scan scans of 960 attachment points in 80 healthy s
-
1 case of combined D-dipolymer stubbornness in combination with primary dry ness syndrome
Time of Update: 2020-05-29
Primary dryness syndrome is a chronic progressive autoimmune disease that is multi-system affected, mainly due to the secretion glands The clinical incidence of the disease is hidden, clinical perf
-
Arthritis Rheumatol: Recombinant adenosine deaminase improves inflammation, vascular disease and fibrosis in preclinical models of systemic sclerosis
Time of Update: 2020-05-29
Systemic sclerosis (SSc) is characterized by fibrosis, vascular disease and inflammation Adenosine signaling plays an important role in fibroblast activation The purpose of this study was to assess
-
Lancet Rheumato: Effect of treatment within 6 weeks of rheumatic symptoms on prognosis
Time of Update: 2020-05-29
The first recommendation of the European Union against Rheumatology for early arthritis treatment is that patients should be treated by a professional rheumatologist within 6 weeks of the onset of
-
J Rheumatol: Correlation between improved disease activity scores in patients with childhood dermatitis and validated original disease activity scores
Time of Update: 2020-05-29
Childhood dermatitis (JDM) is a rare disease that can be treated in children, but patients may be exposed to long-term effects of the disease Clinical trials are needed to find better treatments Th
-
Clin Exp Rheumatol: Midax spinal arthritis patients with cervical artery ultrasound reclassified as hyper-high-risk cardiovascular risk
Time of Update: 2020-05-29
Subclinical atherossclerosis, defined as the presence of cervical plaques, is more common in patients with midashaft spinal arthritis (axSpA) than in healthy individuals The study was designed to d
-
Ann Rheum Dis: Bimekizumab Double Middle and Lemynesin-17A and 17F Therapeutic Aggressive Syllitis
Time of Update: 2020-05-29
Bimekizumab selective lymes (IL)-17A and IL-17F The efficacy and safety of bimekizumab in a phase IIb dose-range study of active syllable scoliosis (AS) are reported here randomly divided adult A
-
CD28/ICOS dual T-cell co-stimulation inhibitor ALPN-101 for the prevention and treatment of acute transplant anti-host disease, while winning the FDA's designation of two orphan drugs
Time of Update: 2020-05-29
Alpine Immune Sciences announced that the U.S Food and Drug Administration (FDA) has designated two orphan drugs for the use of its ALPN-101 (Selective Dual T-Cell Costimulation Factor Inhibitor) f
-
J Rheumatol: The efficacy of continuous and intermittent ceresibu treatment of osteoarthritis
Time of Update: 2020-05-29
The purpose of this study was to determine whether "continuous" ceresib was more effective than "intermittent" in preventing knee and/or hip osteoarthritis (OA) flares a double-blind, randomized
-
Lilly announces clinical study to evaluate JAK inhibitors Olumiant and antiangitosin-2 mono-antilyialysis LY3127804 for treatment of new coronavirus COVID-19 patients
Time of Update: 2020-05-29
Lilly announced that it has reached an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to begin testing Olumiant as a potential treatment for patients hospitalized
-
Ann Rheum Dis: Serum metabolism group and lipid group differences identified potential biomarkers of seronegative rheumatoid arthritis vs psoriasis arthritis
Time of Update: 2020-05-29
Due to similar symptoms and lack of reliable clinical markers, it is often difficult to identify seronegative rheumatoid arthritis ( negRA ) and psoriasis arthritis ( PsA ) to diagnose Since ch
